Health Economic Perspectives in Fibromyalgia: Focus on Pregabalin

home / publications / supplement / a291_2010mayfibromyalgia

Impact of a Prior Authorization for Pregabalin on Health Plan Drug Expenditures

Gary Bazalo, MS, MBA;Richard C. Weiss, MS;Ashish V. Joshi, PhD

ArticleARTICLES

ArticleARTICLES

Pregabalin: An Alpha2-delta (a2-d) Ligand for the Management of Fibromyalgia

Lesley Arnold, MD;Philip Mease, MD;Stuart Silverman, MD

ArticleARTICLES

Financial and Clinical Characteristics of Fibromyalgia: A Case-Control Comparison

Ana Palacio, MD, MPH;Claudia L. Uribe, MD, MHA;Hua Li, MD, PhD;John Hanna, MBA;Michael Deminski, MS, RPh;Jose Alvir, DrPH;Arthi Chandran, MPH;Robert Sanchez, RPh, MS

ArticleARTICLES

Initial Use of Pregabalin, Patterns of Pain-Related Pharmacotherapy, and Healthcare Resource Use Among Older Patients With Fibromyalgia

Mugdha Gore, PhD, BPharm;Alesia Sadosky, PhD, MPH, MBA;Gergana Zlateva, PhD;Daniel Clauw, MD

ArticleARTICLES

ArticleSupplements

Participating Faculty

ArticleSupplements

Patterns of Healthcare Utilization and Cost in Patients With Newly Diagnosed Fibromyalgia

Ariel Berger, MPH;Alesia Sadosky, PhD, MPH, MBA;Ellen M. Dukes, PhD;John Edelsberg, MD, MPH;Gergana Zlateva, PhD;Gerry Oster, PhD

ArticleARTICLES

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions